skeleton. PT+MTX combines the toxic effects of both drugs. In the in vivo setting, the antitumoral activity of drugs differs from their in vitro cytotoxicity, but their combination effects are more pronounced. MTX on its own does not display significant antitumoral activity, whereas PT reduces tumor growth in both L1210 and KB in vivo models. Consistent with the cell cycle effects, MTX combined at moderate dose boosts the antitumoral effect of PT in both in vivo tumor models. Therefore, the PT+MTX combination may present a promising therapeutic approach for different types of cancer.
are used widely in the clinics. By either stabilizing or destabilizing microtubules, they lead to a disruption of the microtubule network and to G2/M arrest. 1 However, given the development of resistances that for instance frequently occur with Vinca alkaloids, the need for new drugs of this class becomes crucial. 2, 3 Tubulysins, a family of natural compounds of myxobacterial origin, are a powerful and highly effective therapeutic group. By binding to the vinca domain of β-tubulin, tubulysins prevent tubulin polymerization which ultimately results in microtubule depletion and apoptosis of the treated cells. 4, 5 Pretubulysin (PT) is a biosynthetic precursor of the tubulysins and better accessible by chemical synthesis. 6, 7 Moreover, it displays remarkable antitumoral potency in the subnanomolar region. 6, 8 PT not only leads to reduced tumor cell growth of different cell lines 6 and inhibits cancer cell migration in vitro, 8 it also shows great potential in vivo: PT inhibits tumor growth 6, [8] [9] [10] [11] and metastasis 6, 12 and also significantly reduces angiogenesis. 8, 10 Antifolates, which belong to the class of antimetabolites, were among the first chemotherapeutic drugs to be investigated for the cure of metastatic cancer. As folate antagonists, they make use of the reduced folate carrier (RFC) or the folate receptor (FR) to enter the cell. [13] [14] [15] The FR is overexpressed in many epithelial tumors and therefore plays an important role in targeted cancer therapy. 16, 17 Methotrexate (MTX) is the most prominent representative of this group. After successfully entering the cell, it competitively inhibits the dihydrofolate reductase (DHFR) and by that the conversion of folic acid to dihydrofolic acid and tetrahydrofolic acid. These are required for the biosynthesis of purines, thus the de novo synthesis of DNA. 18 However, acquired resistance to MTX represents a common problem of monotherapy approaches. [19] [20] [21] This hurdle can possibly be overcome by combining MTX with a second antitumoral agent.
Combination therapy is an approach that combines two or more therapeutic agents in order to address several targets, possibly reduce resistance formation and increase the therapeutic efficacy while potentially decreasing dosages. 22, 23 Already in 1965, a combination chemotherapy approach referred to as POMP regimen was successfully administered. Apart from MTX, it contained 6-mercaptopurine, vincristine, and prednisone and resulted in long-term remission in children with acute lymphocytic leukemia. 24, 25 In a previous experiment, in which the novel tubulin inhibitor PT was conjugated with MTX-containing oligomers for FR-targeted delivery, we searched for a possible combination effect. 11 Hence, this drug combination was chosen in this study to further boost the encouragingly high potency of PT. The combination of both drugs was analyzed in terms of cytotoxicity, apoptosis, its influence on the tumor cell cycle and the cytoskeleton. Moreover, in vivo antitumor activity of the combination approach was evaluated in a treatment experiment in two tumor mouse models. All experiments were performed in L1210 leukemia and KB cervix carcinoma cells since both are sensitive to PT and MTX. Furthermore, MTX has been well established for the treatment of leukemia. ) were added to each well and incubated for 2 hours in a cell culture incubator.
| MATERIALS AND METHODS

| Materials
After formazan formation, medium and MTT were removed, and cells were frozen at −80°C. liters of the viscous cell suspension were added to a microscope slide, the cover slip was carefully placed on top of the drop. The cover slip was sealed with nail polish. After drying, the prepared microscope slides were used for microscopy.
| In vivo experiments
Murine leukemia tumor model 
| Statistical analysis
Results are expressed as mean + SD if not indicated elsewise. Statistical analysis was performed with unpaired student's t test using
GraphPad Prism ™ and P < 0.05 were considered as significant (*P < 0.05; **P < 0.01; ***P < 0.001; ****P < 0.0001; ns = no significance). 
| Confocal laser scanning microscopy of drugtreated cells
The effects of PT, MTX, and PT+MTX on the DNA, the actin cytoskeleton and on the microtubules of L1210 and KB cells were determined by confocal laser scanning microscopy (CLSM). Figure 4 depicts the disruption of the microtubule network of L1210 and KB cells caused by PT treatment, already after 24 hours treatment (see also Figure S5 for nonmerged images). L1210 cells have lost their structural integrity, the microtubule network seems to be located ) refers to the concentration of PT, the concentration is 3-fold higher for MTX, due to the 1:3 molar drug ratio (**P < 0.01; ***P < 0.001; ****P < 0.0001) Treatments were performed in triplicates (mean + SD; n = 3; *P < 0.05; **P < 0.01; ***P < 0.001; ****P < 0.0001)
F I G U R E 3 Apoptosis in drug-treated L1210 cells (A) or KB cells (B)
. Cells were treated with control buffer HEPES buffered glucose (HBG), pretubulysin (PT), methotrexate (MTX), or PT + MTX and incubated for 24, 48, and 72 hours, respectively. Cells were stained with annexin V-FITC and propidium iodide and analyzed by flow cytometry. Treatments were performed in triplicates (mean + SD; n = 3; **P < 0.01; ***P < 0.001; ****P < 0.0001). After the treatment start, tumor growth in the HBG-injected group proceeded rapidly, so the first animal had to be sacrificed after 9 days. Tumor growth in MTX-treated animals was slightly slowed down after 1 week of treatments and the first animal was sacrificed after 12 days. Notably, tumor growth in both PT containing groups was retarded from the first injection on and could be further inhibited in the PT+MTX combination group ( Figure 6A ). While the first animal of the PT group had to be sacrificed on day 15 after treatment start, PT+MTX combination led to a survival of all animals until day 21. Figure 6B The weight of animals was monitored regularly; the unobtrusive weight development in all groups indicates that treatments were well tolerated by the animals ( Figure S6B ). Regarding the effects of the drugs on the cell cycle, our experiments confirm the expected G2/M arrest of PT-treated cells 6, 8, 34 and G1/S arrest by MTX. 35, 36 Remarkably, G2/M arrest mediated by PT+MTX combination went far beyond the effect of PT alone. One explanation for the predominance of the PT effect on the cell cycle might be its more direct way of interference. PT binds to tubulin and thereby directly affects the working of the cell division cycle.
MTX on the other hand influences the G1/S stage of the cell cycle more indirectly. MTX is essentially a prodrug. In order to bind its target enzyme DHFR, MTX must be polyglutamylated intracellularly.
After polyglutamylation, MTX inhibits the synthesis of the co-factor tetrahydrofolate and thus, the C1 metabolism. As a result, no nucleotides are synthesized which would be essential for DNA synthesis. [42] [43] [44] Treatment with microtubule depolymerizing drugs increases contractility in fibroblasts. Additionally, rapid restoration of actin-containing stress fibers is induced, even after their previous disruption. 44 The authors offer several possible explanations. In contrast to cell culture cytotoxicity, a lack of antitumoral activity of MTX was observed in vivo at the applied dosage of 5 mg kg
, which is supported by previous studies. 45, 46 The dosage of MTX used in the mouse experiments was based on efficacy in cell culture.
Burger et al described 100 mg kg −1 as the maximum tolerated dose of MTX for NMRI-nude mice. 47 In our additional MTX dose finding experiments, even after multiple injections with the highest tolerated dose of 80 mg kg −1 , we did not observe any significant L1210 tumor growth inhibition in vivo. An acquired chemoresistance against MTX can be excluded, since the MTX-treated tumors are still MTX sensitive in cell culture. On the other hand, PT at the well-tolerated 2 mg kg −1 dose exhibited a clear antitumoral effect on L1210 tumors in vivo. This is also in accordance with our recent work in combining PT with antitumoral EG5 siRNA. 9 Encouragingly, this favorable PT effect could be further enhanced by the co-administration of the rather low dose of 5 mg kg −1 MTX, resulting in a significantly retarded tumor growth in the combination group. The boosting effect of low dose MTX is remarkable, considering the lack of antitumoral effects of the single drug at even 20-fold higher dose.
In the KB human cervix carcinoma tumor model, PT had already previously demonstrated antitumoral effects. 11 In this study, the antitumoral activity of 2 mg kg −1 PT could be confirmed, while MTX only slightly inhibited KB tumor growth. This is consistent with the known in vitro chemoresistance of KB cells to MTX 48 and in vivo studies. 46 Importantly, also in this carcinoma model, the co-administration of 
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